DSPG3 Inhibitors
Chemical inhibitors of DSPG3 can act through various pathways to reduce its functional activity within bone and cartilage matrix formation. Alendronate, pamidronate, risedronate, and zoledronic acid are all bisphosphonates that inhibit osteoclast-mediated bone resorption. This inhibition has a downstream effect on the bone formation process, wherein DSPG3 is involved. By reducing the rate of bone resorption, these chemicals indirectly lessen the demand for bone remodeling and the subsequent need for DSPG3's role in the organization and mineralization of the bone matrix. Moreover, fluoride incorporation into bone apatite can alter mineralization, thereby disrupting the normal function of DSPG3 in bone development. Similarly, strontium ranelate's dual effect on bone metabolism balances bone formation and resorption, which can alter the requirement for DSPG3 in maintaining bone structure.
Cytotoxic agents like methotrexate, cytarabine, cyclophosphamide, and hydroxyurea target cellular proliferation, which includes osteoblasts, the primary cells responsible for new bone formation that interacts with DSPG3. By inhibiting the proliferation of osteoblasts, these chemicals indirectly diminish the functional role of DSPG3 in bone matrix assembly. Heavy metals such as cadmium, in the form of cadmium chloride, can cause bone demineralization, affecting bone cell function and, consequently, the role of DSPG3 in cartilage structure and bone matrix organization. Excessive copper sulfate impacts bone metabolism, which can also indirectly affect DSPG3 activity in bone and cartilage by influencing the cells responsible for matrix formation and mineralization, where DSPG3 is a key component.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alendronate acid | 66376-36-1 | sc-337520 | 5 g | $135.00 | 2 | |
Alendronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption. DSPG3 is a proteoglycan found in cartilage and is associated with bone development and calcification. By inhibiting osteoclast activity, alendronate can lead to reduced bone resorption, thereby potentially reducing the remodeling and turnover of bone that would necessitate the action of DSPG3 in bone development and maintenance. | ||||||
Zoledronic acid, anhydrous | 118072-93-8 | sc-364663 sc-364663A | 25 mg 100 mg | $92.00 $256.00 | 5 | |
Zoledronic acid, a third-generation bisphosphonate, strongly inhibits osteoclast-mediated bone resorption. The reduction in bone turnover and remodeling indirectly lowers the functional need for DSPG3 in bone and cartilage, as the protein contributes to the organization and mineralization of the bone matrix. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Methotrexate is a dihydrofolate reductase inhibitor that can lead to reduced proliferation of cells, including osteoblasts. As osteoblasts are responsible for bone formation and are likely to interact with DSPG3 during this process, methotrexate's action can indirectly limit the role of DSPG3 in new bone formation by reducing osteoblast activity. | ||||||
1-β-D-Arabinofuranosylcytosine | 147-94-4 | sc-201628 sc-201628A sc-201628B sc-201628C sc-201628D | 1 g 5 g 25 g 100 g 250 g | $150.00 $263.00 $518.00 $731.00 $1461.00 | 1 | |
1-β-D-Arabinofuranosylcytosine is a nucleoside analog that inhibits DNA synthesis. By reducing the proliferation of osteoblasts, the cells in bone that would interact with DSPG3, cytarabine can indirectly reduce the functional requirement for DSPG3 in bone matrix formation and remodeling. | ||||||
Cyclophosphamide | 50-18-0 | sc-361165 sc-361165A sc-361165B sc-361165C | 50 mg 100 mg 500 mg 1 g | $90.00 $146.00 $469.00 $791.00 | 18 | |
Cyclophosphamide is an alkylating agent used to reduce cellular proliferation. By limiting the activity of cells involved in bone turnover and formation, cyclophosphamide can indirectly reduce the need for DSPG3 activity in the bone matrix assembly and cartilage structure. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $78.00 $260.00 | 18 | |
Hydroxyurea inhibits ribonucleotide reductase, leading to reduced DNA synthesis and cell proliferation. This inhibitory effect on osteoblasts can indirectly reduce the functional demand for DSPG3 in bone matrix formation and mineralization. | ||||||
Sodium Fluoride | 7681-49-4 | sc-24988A sc-24988 sc-24988B | 5 g 100 g 500 g | $40.00 $46.00 $100.00 | 26 | |
Fluoride ions can incorporate into the bone apatite structure, altering the bone mineralization process. High levels of fluoride disrupt normal bone formation, which could indirectly decrease the physiological function of DSPG3 in the process of bone development and calcification. | ||||||
Cadmium chloride, anhydrous | 10108-64-2 | sc-252533 sc-252533A sc-252533B | 10 g 50 g 500 g | $56.00 $183.00 $352.00 | 1 | |
Cadmium exposure can lead to bone demineralization and disrupt the function of cells involved in bone metabolism. This disruption can indirectly reduce the functional role of DSPG3, as it is involved in cartilage structure and bone matrix organization. | ||||||
Strontium Ranelate | 135459-87-9 | sc-208403 | 10 mg | $320.00 | ||
Strontium ranelate is known to affect bone metabolism, promoting bone formation while inhibiting bone resorption. Its influence on osteoblast and osteoclast activity can indirectly alter the requirement for DSPG3 during bone and cartilage formation and maintenance. | ||||||
Copper(II) sulfate | 7758-98-7 | sc-211133 sc-211133A sc-211133B | 100 g 500 g 1 kg | $46.00 $122.00 $189.00 | 3 | |
Copper is an essential trace element that, in excess, can lead to alterations in bone metabolism and structure. An imbalance in copper levels can indirectly impact the role of DSPG3 in bone and cartilage by affecting the cells responsible for matrix formation and mineralization, where DSPG3 is a critical component. | ||||||